Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Radiol Case Rep ; 15(3): 9-18, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34267866

RESUMO

Schwannomas of the prostate are a rare entity and usually diagnosed incidentally following surgical management of presumed benign prostate hyperplasia or prostate adenocarcinoma. We present a case of sporadic periprostatic schwannoma diagnosed in conjunction with multifocal prostate adenocarcinoma on pre-operative multiparametric magnetic resonance imaging.


Assuntos
Adenocarcinoma/diagnóstico , Neurilemoma/diagnóstico , Neoplasias da Próstata/diagnóstico , Adenocarcinoma/diagnóstico por imagem , Idoso , Diagnóstico Diferencial , Humanos , Linfadenopatia/diagnóstico , Imageamento por Ressonância Magnética , Masculino , Neurilemoma/diagnóstico por imagem , Neoplasias da Próstata/diagnóstico por imagem
2.
Semin Diagn Pathol ; 38(5): 54-61, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33985831

RESUMO

An understanding of the molecular pathology of non-small cell lung cancer (NSCLC) is important for pathologists as molecular characterization is now required for treatment decisions in advanced stage disease. While assessment for EGFR mutations, ALK and ROS1 fusions, and in some countries BRAF mutations, is now standard practice, other oncogenic mutations are also emerging that may impact routine clinical practice including alterations involving KRAS, NTRK, RET, MET and HER2. In addition, molecular pathology alterations of NSCLC are associated with responses to immune checkpoint therapy and are being increasingly investigated. Finally, specific molecular pathological alterations define some rarer subtypes of NSCLC such as salivary gland tumours, NUT carcinoma and SMARCA4-deficient undifferentiated tumour, and an understanding of the molecular pathology is important for their accurate diagnosis. In this review, the molecular pathology of NSCLC is discussed with a focus on clinically relevant molecular alterations.

3.
Chest ; 159(2): e119-e126, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33563454

RESUMO

CASE PRESENTATION: A 72-year-old Chinese man presented with a 5-month history of chronic dry cough, weight loss, and progressive dyspnea. There was no associated hemoptysis, hoarseness, epistaxis, or fever on systemic review. He was a nonsmoker and had no family history of malignancy. He was treated for pulmonary TB 40 years ago. A chest radiograph (Fig 1) showed mass-like consolidation in the right midzone with loss of the right hilar border, a small right pleural effusion, and bi-apical scarring. On physical examination, he was afebrile and normotensive, and he had pulse oxygen saturation of 97%. Examination of the chest was remarkable only for reduced breath sounds over the right chest. He did not have digital clubbing, distended neck veins, or cervical lymphadenopathy.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Infecções por Vírus Epstein-Barr/complicações , Neoplasias Pulmonares/diagnóstico , Idoso , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/terapia , Carcinoma Pulmonar de Células não Pequenas/virologia , Tosse , Diagnóstico Diferencial , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/terapia , Neoplasias Pulmonares/virologia , Masculino , Metástase Neoplásica , Estadiamento de Neoplasias
4.
Int J Radiat Oncol Biol Phys ; 108(1): 70-80, 2020 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-32544576

RESUMO

PURPOSE: Improved antitumor responses have been observed in patients after combination radiation therapy (RT) and immune checkpoint blockade (ICB). Whether these clinical responses are linked to the host systemic immune system has not been elucidated. METHODS AND MATERIALS: In this single-institution prospective observational study, peripheral blood was longitudinally collected from 10 patients with metastatic disease who had responded to anti-PD-1/anti-PD-L1 ICB and received RT (8-50 Gy in 1-5 fractions) upon disease progression at the following timepoints: baseline (pre-RT), 1 to 2 weeks post-RT, and post-ICB (cycle 1) on reintroduction post-RT. To thoroughly characterize the interaction between combined RT-ICB and the host immune system, we performed high-dimensional, mass cytometry-based immunophenotyping of circulating lymphocytes using a 40-marker panel addressing lineage, differentiation, activation, trafficking, cytotoxicity, and costimulatory and inhibitory functions. Phenotypic expression of circulating lymphocytes was compared across patients and time points and correlated with post-RT tumor responses. RESULTS: Foremost, we demonstrated excellent posttreatment clinical responses, including 4 local responses with >50% reduction in radiated tumor size, 1 out-of-field response, and 4 patients who resumed ICB for >1 year. Baseline and post-RT immune states were highly heterogeneous among patients. Despite this interindividual heterogeneity in baseline immune states, we observed a systemic immune reaction to RT-ICB common across patients, histology, and radiation sites; a subset of pre-existing Ki-67+ CD8+ T cells were increased post-RT and further expanded upon reintroduction of ICB post-RT (2.3-fold increase, P = .02). Importantly, RT did not alter the phenotypic profile of these Ki-67+ CD8+ T cells, which was characterized by a distinct activated and differentiated effector phenotype. CONCLUSIONS: Collectively, these findings point toward a sustained reinvigoration of host antitumor immunity after RT-ICB and suggest an expansion in activated Ki-67+ CD8+ T cells as a possible demonstration of this synergy, thereby providing new insights that may support the development of optimal sequencing strategies.


Assuntos
Inibidores de Checkpoint Imunológico/farmacologia , Radioterapia , Antígeno B7-H1/metabolismo , Linhagem Celular Tumoral , Sobrevivência Celular/imunologia , Sobrevivência Celular/efeitos da radiação , Terapia Combinada , Humanos , Imunofenotipagem , Células Matadoras Naturais/citologia , Células Matadoras Naturais/imunologia , Células Matadoras Naturais/efeitos da radiação , Linfócitos T/citologia , Linfócitos T/imunologia , Linfócitos T/efeitos da radiação
5.
Zhongguo Zhong Yao Za Zhi ; 40(19): 3889-93, 2015 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-26975120

RESUMO

INDENA SPA Company in Italy is a multi-national company that produces and sells plant extracts. Based on its own re- search advantages in the field of Ginkgo biloba preparation, the company protects its own products market effectively through building patent portfolio around the patents of its opponent. Based on the multi-angle analysis for patent portfolio of G. biloba preparation from the aspects of application time, legal status, technical development route, and patent portfolio layout, this article provides technical reference on research and development of G. biloba preparation, and the author suggest that Chinese applicants learn techniques and layout experiences of other patents fully to enhance the level of research and patent protection level.


Assuntos
Química Farmacêutica/legislação & jurisprudência , Ginkgo biloba/química , Extratos Vegetais/química , Química Farmacêutica/economia , Itália , Patentes como Assunto , Extratos Vegetais/economia , Extratos Vegetais/isolamento & purificação
6.
Zhongguo Zhong Yao Za Zhi ; 39(17): 3384-8, 2014 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-25522634

RESUMO

SCHWABE Company in German is the first and largest manufacturer of Ginkgo biloba preparation. The company not only has leading technology in this field, but also protects its own market effectively through the high quality of patent drafting and exactly patent layout. Based on multi-angle analysis for patent portfolio of G. biloba preparation at application time, legal status, globally layout, Chinese layout, the article provides technical reference of research and development of G. biloba, also provides valuable experience of traditonal Chinese medicine patent portfolio layout for Chinese enterprises.


Assuntos
Indústria Farmacêutica/legislação & jurisprudência , Ginkgo biloba/química , Patentes como Assunto/legislação & jurisprudência , Preparações de Plantas/isolamento & purificação , Indústria Farmacêutica/economia , Indústria Farmacêutica/tendências , Humanos , Fitoterapia/economia , Fitoterapia/tendências , Tecnologia Farmacêutica/economia , Tecnologia Farmacêutica/tendências
7.
Zhongguo Zhong Yao Za Zhi ; 38(17): 2889-93, 2013 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-24380318

RESUMO

With related global patent data as analysis samples, worldwide patent overview of Ginkgo biloba preparation is analyzed in application, applicant, technical distribution and so on. This research shows that the most important areas of G. biloba preparation are Europe and China. The European applicants start earliest along with developing smoothly, moreover, their patents have best quality. The Chinese applicants start late along with the fastest growing, and have already certain research capabilities, moreover, their patents' quality needs to be improved. This research result provides reference for development of G. biloba preparation. The author suggest that Chinese applicants learn techniques and layout experiences of other's patents fully to enhance the level of new drug development and patent protection.


Assuntos
Química Farmacêutica/legislação & jurisprudência , Ginkgo biloba/química , Patentes como Assunto/legislação & jurisprudência , Produtos Biológicos , Química Farmacêutica/métodos , Química Farmacêutica/organização & administração , China , Europa (Continente) , Humanos , Recursos Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...